Financials data is unavailable for this security.
View more
Year on year Fate Therapeutics Inc had revenues fall -34.03% from 96.30m to 63.53m, though the company grew net income from a loss of 281.72m to a smaller loss of 160.93m.
| Gross margin | -- |
|---|---|
| Net profit margin | -1,426.67% |
| Operating margin | -1,587.28% |
| Return on assets | -31.56% |
|---|---|
| Return on equity | -42.10% |
| Return on investment | -33.99% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Fate Therapeutics Inc fell by 19.51m. However, Cash Flow from Investing totalled 112.67m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 132.26m for operations while cash generated from financing totalled 85.00k.
| Cash flow per share | -1.51 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.49 |
|---|---|
| Tangible book value per share | 3.49 |
More ▼
Balance sheet in USDView more
| Current ratio | 9.18 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
